Alan Baik, MD

Assistant Professor

I am a cardiologist with an expertise in cardio-oncology. Cardio-oncology is an emerging field in cardiovascular medicine that is focused on the cardiovascular care of cancer patients and survivors who have developed cardiovascular disease from their cancer-directed therapies. These therapies include traditional chemotherapy, immunotherapy, targeted therapy, and radiation therapy, among others. Cancer patients are at increased risk of cardiovascular disease, and this can be further exacerbated by their cancer-directed therapies, which can cause a myriad of cardiovascular problems, such as cardiomyopathy, heart failure, arrhythmias, hypertension, pericardial disease, valvular disease, and metabolic syndrome. I work closely with oncologists and other providers in a multidisciplinary team to optimize the cardiovascular care of cancer patients.

I am also a physician-scientist with a research focus on how cells, tissues, and organisms respond and adapt to low oxygen (hypoxia) and high oxygen (hyperoxia) states. I am studying novel ways cells and tissues respond to states of low oxygen and why high oxygen is toxic at the cellular and systemic levels.

Education
06/2021 - Cardiovascular Medicine, University of California, San Francisco
06/2017 - Internal Medicine, University of California, San Francisco
MD, 06/2014 - Medicine, University of California, San Francisco
AB, 05/2008 - Biology, Harvard College
Honors and Awards
  • Burroughs Wellcome Fund Career Award for Medical Scientists, 2024-2029
  • American Heart Association-Harold Amos Medical Faculty Development Program, 2024
  • Distinguished Achievement in Science Award, Gladstone Institutes, 2023
  • Chan-Zuckerberg Biohub Physician-Scientist Fellow, 2021-2023
  • Sarnoff Scholar Career Development Award, 2021-2023
  • T32 NIH Institutional Training Grant, 2019-2021
  • UCSF Dean's Award in Molecular Medicine, 2014
  • Sarnoff Cardiovascular Research Fellowship (2nd Year Fellow), 2012-2013
  • Sarnoff Cardiovascular Research Fellowship (1st Year Fellow), 2011-2012
Publications

  1. Dillon HT, Foulkes SJ, Baik AH, Scott JM, Touyz RM, Herrmann J, Haykowsky MJ, La Gerche A, Howden EJ. Cancer Therapy and Exercise Intolerance: The Heart Is But a Part: JACC: CardioOncology State-of-the-Art Review. JACC. CardioOncology 2024. PMID: 39239327


  2. Power JR, Dolladille C, Ozbay B, Procureur AM, Ederhy S, Palaskas NL, Lehmann LH, Cautela J, Courand PY, Hayek SS, Zhu H, Zaha VG, Cheng RK, Alexandre J, Roubille F, Baldassarre LA, Chen YC, Baik AH, Laufer-Perl M, Tamura Y, Asnani A, Francis S, Gaughan EM, Rainer PP, Bailly G, Flint D, Arangalage D, Cariou E, Florido R, Narezkina A, Liu Y, Sandhu S, Leong D, Issa N, Piriou N, Heinzerling L, Peretto G, Crusz SM, Akhter N, Levenson JE, Turker I, Eslami A, Fenioux C, Moliner P, Obeid M, Chan WT, Ewer SM, Kassaian SE, International ICI-Myocarditis Registry, Johnson DB, Nohria A, Zadok OIB, Moslehi JJ, Salem JE. Predictors and Risk Score for Immune Checkpoint-Inhibitor-Associated Myocarditis Severity. medRxiv : the preprint server for health sciences 2024. PMID: 38883792


  4. Lassen MCH, Arya F, Biering-Sørensen T, Reeh JLT, Melisko ME, Sarwary S, Baik AH, Aras MA, Qasim A. Left atrial strain is reduced following trastuzumab in breast cancer patients. Echocardiography (Mount Kisco, N.Y.) 2024. PMID: 38284677


  5. Chen X, Haribowo AG, Baik AH, Fossati A, Stevenson E, Chen YR, Reyes NS, Peng T, Matthay MA, Traglia M, Pico AR, Jarosz DF, Buchwalter A, Ghaemmaghami S, Swaney DL, Jain IH. In vivo protein turnover rates in varying oxygen tensions nominate MYBBP1A as a mediator of the hyperoxia response. Science advances 2023. PMID: 38064566


  6. Patel K, Hsu KY, Lou K, Soni K, Lee YJ, Mulvey CK, Baik AH. Osimertinib-induced biventricular cardiomyopathy with abnormal cardiac MRI findings: a case report. Cardio-oncology (London, England) 2023. PMID: 37908018


  7. Addison D, Branch M, Baik AH, Fradley MG, Okwuosa T, Reding KW, Simpson KE, Suero-Abreu GA, Yang EH, Yancy CW, American Heart Association Cardio-Oncology Committee of the Council on Clinical Cardiology and Counc. Equity in Cardio-Oncology Care and Research: A Scientific Statement From the American Heart Association. Circulation 2023. PMID: 37377045


  8. Baik AH, Haribowo AG, Chen X, Queliconi BB, Barrios AM, Garg A, Maishan M, Campos AR, Matthay MA, Jain IH. Oxygen toxicity causes cyclic damage by destabilizing specific Fe-S cluster-containing protein complexes. Molecular cell 2023. PMID: 36893757


  10. Baik AH. Hypoxia signaling and oxygen metabolism in cardio-oncology. 2015 Year Book of Pediatrics. Ed. Cabana MD. (Elsevier; Philadelphia, PA) 2022. PMID: 34979102


  11. Lehmann LH, Cautela J, Palaskas N, Baik AH, Meijers WC, Allenbach Y, Alexandre J, Rassaf T, Müller OJ, Aras M, Asnani AH, Deswal A, Laufer-Perl M, Thuny F, Kerneis M, Hayek SS, Ederhy S, Salem JE, Moslehi JJ. Clinical Strategy for the Diagnosis and Treatment of Immune Checkpoint Inhibitor-Associated Myocarditis: A Narrative Review. JAMA cardiology 2021. PMID: 34232253


  12. Baik A, Oluwole OO, Johnson DB, Shah N, Salem JE, Tsai KK, Moslehi JJ. Mechanisms of Cardiovascular Toxicities Associated with Immunotherapies. Volume 128 of Issue 11. 2021. PMID: 33934609


  13. Asnani A, Moslehi JJ, Adhikari BB, Baik AH, Beyer AM, de Boer RA, Ghigo A, Grumbach IM, Jain S, Zhu H, American Heart Association Council on Basic Cardiovascular Sciences; Cardio-Oncology Science Subcomm. Preclinical Models of Cancer Therapy-Associated Cardiovascular Toxicity: A Scientific Statement From the American Heart Association. Volume 129 of Issue 1. 2021. PMID: 33934611


  14. Baik AH, Tsai KK, Oh DY, Aras MA. Mechanisms and clinical manifestations of cardiovascular toxicities associated with immune checkpoint inhibitors. Clinical science (London, England : 1979) 2021. PMID: 33686402


  15. John R Power, Joachim Alexandre, Arrush Choudhary, benay ozbay, Nicolas L Palaskas, Lorenz H Lehmann, Daniel Finke, Jennifer Cautela, Franck Thuny, Yuichi Tamura, Salim S Hayek, Tariq U Azam, Aarti Asnani, Tyler Mehegan, Mandar A Aras, Alan H Baik, Lauren Gilstrap, Michal Laufer-Perl, Dimitri Arangalage, Steven Ewer, Matthew Martini, Joseph Nowatzke, Olusola A Orimoloye, Douglas M Brinkley, Wouter C Meijers, Charlotte Fenioux, Stephane EDERHY, Javid J Moslehi, Joe-elie Salem. Abstract 14843: Electrocardiographic Manifestations of Immune Checkpoint Inhibitor Associated Myocarditis. Circulation 2020. PMID:


  16. Joseph Nowatzke, John R Power, Wouter C Meijers, Olusola Orimoloye, Charlotte Fenioux, Yuichi Tamura, Jennifer Cautela, Lorenz H Lehmann, Daniel Finke, Salim Hayek, Tariq U Azam, Aarti Asnani, Tyler Mehegan, Alison Weppler, Alan H Baik, Mandar A Aras, Anna Narezkina, Dimitri Arangalage, fanny rocher, Gerard Alexandre, Nicolas L Palaskas, Joe-elie Salem, Javid Moslehi. Abstract 15365: Natural History of Immune Checkpoint Inhibitor Associated Myocarditis With Preserved Ejection Fraction. Circulation 2020. PMID:


  17. Baik AH, Jain IH. Turning the Oxygen Dial: Balancing the Highs and Lows. Volume 30 of Issue 7. 2020. PMID: 32386878


  18. Olenchock BA, Moslehi J, Baik AH, Davidson SM, Williams J, Gibson WJ, Chakraborty AA, Pierce KA, Miller CM, Hanse EA, Kelekar A, Sullivan LB, Wagers AJ, Clish CB, Vander Heiden MG, Kaelin WG. EGLN1 Inhibition and Rerouting of a-Ketoglutarate Suffice for Remote Ischemic Protection. Volume 165 of Issue 2. 2016. PMID: 27058668


  19. Alan Baik, Ben Olenchock, Javid Moslehi, William G. Kaelin. ACUTE HYPOXIA-INDUCIBLE FACTOR EGLN1 INACTIVATION PROTECTS AGAINST ISCHEMIA-REPERFUSION INJURY BY REGULATION OF GLUCOSE OXIDATION AND REACTIVE OXYGEN SPECIES GENERATION. Journal of the American College of Cardiology 2013. PMID:


  20. Stewart FJ, Baik AH, Cavanaugh CM. Genetic subdivision of chemosynthetic endosymbionts of Solemya velum along the Southern New England coast. Volume 75 of Issue 18. 2009. PMID: 19633116